Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are seeing how well the combination of glofitamab and lenalidomide works against lymphoma. The people in this study have mantle cell lymphoma (MCL) that keeps growing even after treatment. Their prior treatment included a drug called a BTK inhibitor.
Researchers want to learn if L19IL2 and L19TNF, alone or together, work well to treat melanoma when given with pembrolizumab. The people in this study have melanoma that has metastasized (spread) or is inoperable (cannot be taken out with surgery). Their cancers keep growing even after having immune-boosting therapy.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to see how well a new combination of drugs works to treat low-grade serous ovarian cancer. The drugs are avutometinib, defactinib, and letrozole. The people in this study have ovarian cancer that cannot be completely removed with surgery.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
The purpose of this study is to find the highest dose of the investigational drug PF-07799933 that can be given alone and in combination with binimetinib or cetuximab in people with advanced solid tumors that have continued to grow despite treatment and contain a mutation in the BRAF gene. A mutated BRAF gene makes a protein that sends signals to cancer cells to grow and divide. While some anti-cancer drugs only work for certain BRAF mutations, the investigational drug PF-07799933 may target all types of BRAF mutant proteins, blocking them from sending these signals and causing cancer cells to die.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
The purpose of this research study is to understand more about smoldering multiple myeloma (SMM). SMM is multiple myeloma that is not yet causing symptoms. It is usually not treated unless it causes symptoms. 
In this study, researchers want to find the best dose of REM-422 to treat leukemia or myelodysplastic syndrome (MDS). The people in this study have acute myeloid leukemia (AML) or higher-risk MDS that keeps growing even with treatment. Higher-risk means the disease has a high chance of coming back or not responding to therapy.
Researchers want to see how well raludotatug deruxtecan (R-DXd) works against advanced solid tumors. The people in this study have the following cancers, which have spread despite treatment:
